GBA1 and Parkinson disease: In February 2021, exactly one year after the publication of the article with the wrong mouse viewpoint, the clinical trial of venglustat GBA1-PD was stopped by Sanofi because venglustat actually ‘did not show any beneficial treatment effect compared to placebo’ [7].